- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03527004
Cross-Sectional Survey on the Use of Tobacco Products - Italy
Cross Sectional Survey on the Use of Tobacco Products in the General Population and in Users of IQOS in Italy (2018-2020)
Study Overview
Status
Conditions
Detailed Description
The aim of the survey is to describe the current and past patterns of use of tobacco products in the general adult population of Italy and in adult IQOS users registered in the IQOS user database of Philip Morris Italia S.r.l. (Italy IQOS User Database), and explore their association with key independent variables. More specifically, the objectives are:
- Estimate the prevalence of current tobacco use status in the study population.
- Describe the past tobacco use status (cigarette, IQOS and other innovative products, including e-cigarettes) in the study population (i.e. never-use, initiation, product use transition, cessation, re-initiation, and relapse).
- Explore the association between self-reported health status and use of tobacco products in the study population.
- Explore the association between patterns of use (including misuse) with motivation to use, perceived quality attributes of IQOS (e.g. risk and self-reported changes since switching to the product, in a number of relevant domains where IQOS may have potential benefits), and consumer's satisfaction in the population of IQOS users in Italy registered in the Italy IQOS User Database.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Luis Prieto, PhD
- Phone Number: +41 58 242 11 11
- Email: luis.prieto@pmi.com
Study Locations
-
-
-
Lausanne, Switzerland, 2000
- Philip Morris Products S.A.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria (all participants, including IQOS users):
- Legally permitted to buy tobacco products in Italy (≥18 years of age).
- Currently residing in Italy.
- Able to read, write and understand Italian.
- Consent to participate in the survey
Inclusion Criteria (IQOS users only):
- Has used more than 100 HEETS tobacco sticks in his or her lifetime.
- Is currently using IQOS.
- Has access to the internet.
- Is not currently employed by Philip Morris International or any of its affiliates
Exclusion Criteria:
- Not meeting the inclusion criteria.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
General Population
Survey on use of tobacco products in the general population of adults living in Italy.
|
Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Italy.
|
IQOS Users
Survey on use of tobacco products in adult current IQOS Users (at the time of survey) living in Italy who are registered in the Italy IQOS User Database and agreed to be contacted for research purposes at the time of registration.
|
Online survey to describe patterns of use in IQOS users residing in Italy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of current tobacco use
Time Frame: Study duration (3 years).
|
Prevalence of current tobacco use status in the study population.
|
Study duration (3 years).
|
Past tobacco use status
Time Frame: Study duration (3 years).
|
Past tobacco use status (cigarette, IQOS and other innovative products) in the study population.
|
Study duration (3 years).
|
Self-reported health status
Time Frame: Study duration (3 years).
|
Association between self-reported health status and use of tobacco products in the study population.
|
Study duration (3 years).
|
Perceived risk
Time Frame: Study duration (3 years).
|
Association between patterns of use with perceived risk.
|
Study duration (3 years).
|
IQOS use experience
Time Frame: Study duration (3 years).
|
Describe the IQOS user experience, including motivation to use, mis-use, satisfaction, and self-reported changes since switching to the product (in a number of relevant domains where IQOS may have potential benefits).
|
Study duration (3 years).
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Pierpaolo Magnani, Philip Morris Products S.A.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- P1-PMX-02-IT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use
-
University of VirginiaVirginia Foundation for Healthy YouthRecruitingTobacco Use | Electronic Cigarette Use | Tobacco Use CessationUnited States
-
Vanderbilt University Medical CenterCompletedTobacco Use | Tobacco Use Cessation
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
British American Tobacco (Investments) LimitedCompletedTobacco Use | Tobacco SmokingUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco DependenceUnited States
-
Philip Morris Products S.A.CompletedSmoking | Tobacco Use | Tobacco SmokingUnited Kingdom
Clinical Trials on Survey on Use of Tobacco Products in the General Population
-
Philip Morris Products S.A.Terminated
-
Philip Morris Products S.A.Terminated
-
Assuta Medical CenterCompletedSleep Disturbance | Attention DeficitIsrael
-
Sabine DieperinkUniversity of Copenhagen; University of Aarhus; Statens Serum InstitutCompletedRheumatoid Arthritis | Staphylococcus Aureus Bacteremia
-
Centre Hospitalier Metropole SavoieCompletedCOVID-19 | Stress Disorders, Post-TraumaticFrance
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Fundació Institut Germans Trias i Pujol; University of Barcelona; Hospital de... and other collaboratorsRecruitingChild, Only | Healthy Diet | Health Behaviour | Mothers | Environmental-Pollution-Related ConditionSpain
-
Centre Hospitalier Universitaire de NīmesCompleted
-
Poitiers University HospitalCompleted
-
Centre Hospitalier Universitaire, AmiensRecruitingSleep | Newborn | Chemical Pollutants ExposureFrance
-
Derince Training and Research HospitalCompleted